Retatrutide in Las Vegas: FDA Status & Research
Retatrutide is an investigational GLP-1, GIP and glucagon receptor agonist. It is not FDA-approved, and FDA states that it cannot be used in compounding under federal law. This page does not offer retatrutide treatment, a waitlist or access through a medical evaluation.
LiveNow Longevity ·
What is retatrutide?
Retatrutide activates three receptor pathways: GLP-1, GIP and glucagon. This distinguishes its investigational mechanism from semaglutide, a GLP-1 receptor agonist, and tirzepatide, a GIP/GLP-1 receptor agonist. More receptor targets alone do not establish better outcomes or safety.
In the published 2023 phase 2 randomized trial of 338 adults, the 12-mg group had an average 24.2% weight reduction at 48 weeks versus 2.1% with placebo. Gastrointestinal adverse events and dose-dependent heart-rate increases were reported. These are results from a defined research population, not LiveNow outcomes, prescribing instructions or a forecast for an individual.
FDA approval and compounding
FDA states that retatrutide is not a component of an approved drug and cannot be used in compounding under federal law. A physician’s assessment, state pharmacy rules or a supplier’s testing certificate does not create an exception to that restriction.
There is no confirmed FDA approval date stated here. Trial announcements, registry listings and research results are not FDA approval. Follow the current FDA source for regulatory status and a study’s official investigators for its actual eligibility and oversight. LiveNow does not offer trial enrollment through this page.
Research products are not approved medicines
Products sold online with research-use labeling should not be taken as evidence of a lawful human treatment source. FDA warns about illegal marketing of unapproved GLP-1 drugs, including retatrutide. We do not provide purchasing links, dosing instructions, treatment deposits or retatrutide waitlists.
Investigational access, if available within an authorized study, is governed by that study’s rules and oversight. A general clinic appointment is not a substitute for study enrollment.
Approved options and cost questions
FDA-approved semaglutide and tirzepatide products have specific labeled indications. Eligibility, formulation, risks and follow-up depend on the individual assessment. An approved active ingredient does not make a compounded preparation FDA-approved.
There is no retatrutide treatment price on this page. If you seek an evaluation for currently available weight-management care, review the evaluation fee and ask for the management fee (laboratory testing included), medication and follow-up costs before committing. No prescription or particular outcome is guaranteed.
Common Questions
Can I buy retatrutide in Las Vegas?
Retatrutide is not an FDA-approved prescription option, and FDA states that it cannot be compounded under federal law. This page does not sell, prescribe or arrange retatrutide treatment.
Can a physician prescribe compounded retatrutide after an evaluation?
No. Physician supervision does not change FDA’s stated federal prohibition on using retatrutide in compounding. A general evaluation is not a route to obtaining it.
When will retatrutide be approved?
No approval date is promised here. FDA review and approval are separate from a trial result or a manufacturer announcement. Check the linked FDA source for current status.
Should I change an existing treatment because of retatrutide research?
Research headlines are not individual treatment advice. Discuss current treatment, side effects and alternatives with your prescribing clinician. No recommendation to stop or switch a medication is made on this page.
General educational information. An individual medical assessment and the exact product’s regulatory status are separate from this guide.